Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
NIBEC Co Ltd logo — company profile

NIBEC Co Ltd

Founded 2004 Korea South Korea South 8 employees Grant Biotechnology, Manufacturing +2

General Information

Company Name NIBEC Co Ltd
Founded Year 2004
Location Korea South Korea South
Employees 8
Industries Biotechnology, Manufacturing, Medical Devices +1
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with NIBEC Co Ltd. To contact NIBEC Co Ltd, visit nibec.co.kr.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NIBEC Co Ltd compare?

A PDF of NIBEC Co Ltd and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NIBEC Co Ltd soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NIBEC Co Ltd

NIBEC Co Ltd is a South Korean company established in 2004 specializing in R&DP of drug and biomaterial based medical devices. Their expertise lies in the development of the target cell penetrating peptide based drug delivery platform, with a focus on global collaboration. The company operates in the Biotechnology, Manufacturing, and Pharmaceutical industries. It recently secured a grant investment on 21 March 2023 from the Crohn's & Colitis Foundation. NIBEC's innovative approach to drug delivery technology makes it an interesting prospect for investors seeking opportunities in the pharmaceutical and biotech sectors.

Business keywords: Medical devices, Drug delivery, Biomaterials, R&D, Cell penetrating peptides, Global collaboration, Innovation, South Korea

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Grant Undisclosed 1
Crohn's & Colitis Foundation
Crohn's & Colitis Foundation
21 Mar 2023

NIBEC Co Ltd Alternatives & Competitors

View All Alternatives
NIBEC Co Ltd vs
FogPharma
FogPharma United States

Until everything is druggable.

Series E
146 employees
Biopharma, Biotechnology
NIBEC Co Ltd vs
Orbit Discovery
Orbit Discovery United Kingdom

Delivering Peptide Enabled Drug Discovery Solutions

Seed
31 employees
Biotechnology, Health Care
NIBEC Co Ltd vs
OliX Pharmaceuticals, Inc.
OliX Pharmaceuticals, Inc. Korea South

Contributing to the Health and Happiness of Mankind with RNAi Technology

Post-IPO Equity
38 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About NIBEC Co Ltd

NIBEC Co Ltd is a company based out of South Korea dedicated R&DP of drug and biomaterial based medical device. Target cell penetrating peptide based drug delivery platform is one of NIBEC's key technology with global collaboration.
NIBEC Co Ltd was founded in 2004.
NIBEC Co Ltd is headquartered in Korea South.
NIBEC Co Ltd operates in Biotechnology, Manufacturing, Medical Devices and Pharmaceutical. Its work centres on Medical devices, Drug delivery, Biomaterials and R&D.
NIBEC Co Ltd has approximately 8 employees.
NIBEC Co Ltd has completed 1 funding round. The latest funding stage is Grant.
Top alternatives and competitors to NIBEC Co Ltd include FogPharma, Orbit Discovery, OliX Pharmaceuticals, Inc., TransPharma Medical, Nuance Biotech Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NIBEC Co Ltd and FogPharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NIBEC Co Ltd, https://bouncewatch.com/company/nibec-co-ltd, updated 28 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout